The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

N/ACompletedNCT00811980

University of Utah60 enrolled

Overview

We will determine if linezolid inhibits cellular activation and production of pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and the justification for further investigations in S. Aureus sepsis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sepsis

Interventions

Linezolid or VancomycinDRUG

Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy, taking no medications, and not recently hospitalized Exclusion Criteria: * Infection (active)

Outcomes

Primary Outcomes

IL-6

Measurement of IL-6 release in response to MRSA.

Time frame: 12 Months

Secondary Outcomes

MCP-1

Measurement of MCP-1 release in response to MRSA.

Time frame: 12 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.